BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1154 related articles for article (PubMed ID: 17338647)

  • 1. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in high-grade lymphoma.
    Zwick C; Murawski N; Pfreundschuh M;
    Semin Hematol; 2010 Apr; 47(2):148-55. PubMed ID: 20350662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for the treatment of diffuse large B-cell lymphomas.
    Held G; Pöschel V; Pfreundschuh M
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
    Tsai D; Moore H; Hardy C; Porter D; Loh E; Vaughn D; Luger S; Schuster S; Stadtmauer E
    Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
    Tobinai K
    Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab: new indication. In aggressive non Hodgkin lymphoma: benefits must be confirmed.
    Prescrire Int; 2003 Aug; 12(66):125-6. PubMed ID: 12906019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.
    Czuczman MS
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):88-96. PubMed ID: 10561023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse large B-cell lymphoma.
    Ng AK
    Semin Radiat Oncol; 2007 Jul; 17(3):169-75. PubMed ID: 17591563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
    Ogura M
    Rinsho Ketsueki; 2008 Oct; 49(10):1434-50. PubMed ID: 18833928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 58.